What does Vyvanse show up as on a drug screen? Vyvanse shows up as amphetamine on standard drug screens — not as methamphetamine, not as lisdexamfetamine specifically, and not as a distinct or separately identified compound. Because Vyvanse (lisdexamfetamine) is a prodrug that converts entirely to dextroamphetamine in the bloodstream, all drug testing technologies detect the dextroamphetamine metabolite, which triggers the same immunoassay response as any other amphetamine-class compound. Standard SAMHSA-5 panel urine drug screens used in most workplace and pre-employment testing do not distinguish between Vyvanse, Adderall, dexamphetamine, or any other amphetamine-containing ADHD medication — the result is simply reported as “amphetamine positive”. If you have a valid prescription, this is resolved through a Medical Review Officer (MRO) process, not grounds for automatic dismissal.
The Fundamental Chemistry: Why Vyvanse Appears as Amphetamine
Understanding what Vyvanse shows up as on a drug screen requires understanding its metabolic pathway:
The metabolic conversion:Lisdexamfetamine dimesylate (Vyvanse) is an inactive prodrug — the molecule consists of dextroamphetamine covalently bonded to L-lysine. After oral absorption, enzymes on red blood cells cleave the L-lysine away, releasing active dextroamphetamine. This means that by the time Vyvanse is circulating in the bloodstream, it has already been converted to dextroamphetamine.
What drug screens detect:Standard immunoassay drug screens — including urine, saliva, and blood tests — detect the presence of amphetamine metabolites, not the parent lisdexamfetamine molecule itself. Since Vyvanse fully converts to dextroamphetamine, it triggers the amphetamine-positive response on any panel that screens for the amphetamine drug class.
The critical distinction — methamphetamine vs. amphetamine:On a confirmatory test (GC-MS or LC-MS/MS), Vyvanse will produce a positive result for dextroamphetamine — NOT methamphetamine. This distinction matters enormously: methamphetamine is almost always associated with illicit use, while dextroamphetamine is a known prescribed medication metabolite. Confirmatory testing can therefore clearly distinguish a legitimate Vyvanse prescription from illicit methamphetamine use.
The Complete Detection Window by Test Type
Detection windows for Vyvanse vary significantly by the testing method used:
Master Detection Table
| Test Type | What Is Detected | Detection Window | Notes |
|---|---|---|---|
| Urine immunoassay (standard) | Amphetamine metabolites | 3–5 days | Most common employment/legal test |
| Blood test | Dextroamphetamine | 8–34 hours | Shortest window; parent compound clears fastest |
| Saliva/oral fluid | Amphetamine | 48–72 hours | Used in roadside/workplace testing |
| Hair follicle | Amphetamine metabolites | Up to 90 days | Longest window; requires ~7 days of new growth |
| Confirmatory (GC-MS/LC-MS/MS) | Dextroamphetamine specifically | Same as urine above | Distinguishes from methamphetamine |
Urine Drug Test (Most Common)
This is the most frequently used screening method in both Australian and US workplace testing contexts:
- Detection window: 3–5 days after the last dose for standard screening
- What is reported: “Amphetamine positive” — no distinction between Vyvanse, Adderall, or dexamphetamine
- Chronic use may extend this window slightly due to tissue accumulation, though this effect is modest at therapeutic doses
- The dextroamphetamine half-life of approximately 12 hours means that most of the active compound is eliminated within 2.5 days (approximately 2–3 half-lives) but metabolites can persist longer
- A single dose is detectable — even one Vyvanse capsule taken on the day of testing will produce a positive amphetamine result
Blood Test
Blood tests are primarily used in clinical and forensic contexts — they are less common in routine employment testing because of the invasiveness of collection and the short detection window:
- Detection window: 8–34 hours for dextroamphetamine in blood
- The parent lisdexamfetamine compound clears from blood within approximately 8 hours — it is then undetectable because conversion to dextroamphetamine is complete
- Dextroamphetamine persists longer — up to 34 hours in blood in some studies — due to its 12-hour half-life
- A study published in a pharmacokinetics journal detected d-amphetamine in plasma for up to 72 hours post-dose in some participants, reflecting individual metabolic variation
Saliva/Oral Fluid Test
Saliva testing is widely used in Australian workplace and roadside settings because of the ease and non-invasive nature of collection:
- Detection window: 48–72 hours after the last dose
- Saliva concentrations of amphetamine can be equal to or higher than plasma concentrations, making oral fluid a sensitive testing medium
- The 2024 pharmacokinetic study (Onlinelibrary/Wiley) found that d-amphetamine in oral fluid reached maximum concentration at approximately 4 hours post-Vyvanse dose — the same timing as plasma peak
- Roadside oral fluid testing in Australian states tests for amphetamine class compounds; Vyvanse taken on the day of driving will produce a positive result
Hair Follicle Test
Hair testing provides the longest detection window and is used in forensic, legal, and some workplace contexts:
- Detection window: Up to 90 days from the last dose
- Hair grows approximately 1 cm per month — a standard 3 cm hair sample (collected from the scalp within 1.5 inches of the root) reflects approximately 90 days of drug use
- Hair testing requires approximately 7–10 days of hair growth after use before the drug is incorporated into the shaft — meaning a very recent dose may not yet appear in hair
- The PMC study specifically examined detection of lisdexamfetamine and its d-amphetamine metabolite in hair and confirmed detectability within the 90-day window
- Hair testing is less common in routine Australian workplace testing but is used in specific industries (mining, transport) with extended detection requirements
The Two-Stage Testing Process: Screening vs. Confirmation
Understanding how drug tests actually work in professional settings is essential for Vyvanse patients navigating workplace testing:
Stage 1: Immunoassay Screening
The initial screening test — typically a urine immunoassay (either point-of-care dipstick or laboratory-based ELISA) — is a presumptive test, not a definitive one:
- It detects the presence of amphetamine-class compounds above a threshold concentration
- The standard SAMHSA cutoff for amphetamines in urine is 500 ng/mL; some workplace tests use lower thresholds
- At this stage, the result is reported as “non-negative” or “presumptive positive” — not a confirmed positive
- Vyvanse at any therapeutic dose will consistently exceed the 500 ng/mL threshold while the drug is in the detection window
Stage 2: Confirmatory Testing (GC-MS or LC-MS/MS)
Any non-negative result from a screening test should be sent for confirmatory analysis using gas chromatography-mass spectrometry (GC-MS) or liquid chromatography-tandem mass spectrometry (LC-MS/MS) — the gold standard for definitive drug identification:
- Confirmatory testing identifies the specific amphetamine compound present — dextroamphetamine, levoamphetamine, methamphetamine, MDMA etc.
- Vyvanse/dextroamphetamine will show dextroamphetamine as the identified compound— not methamphetamine
- This is the critical distinguishing step: illicit methamphetamine use produces methamphetamine AND dextroamphetamine metabolites; prescribed Vyvanse produces only dextroamphetamine
- The PMC case report (Detection of lisdexamfetamine and its metabolite d-amphetamine, 2022) specifically notes that in confirmatory testing, the absence of methamphetamine alongside dextroamphetamine is a key indicator of therapeutic (not illicit) amphetamine use
The Medical Review Officer (MRO) Process: How a Prescription Protects You
For any workplace drug test conducted under a standard program, a non-negative result triggers the Medical Review Officer (MRO) process — which is where your Vyvanse prescription resolves the positive:
What is an MRO?A Medical Review Officer is a licensed physician specifically trained to review and interpret drug test results — they are the independent expert who determines whether a positive result is clinically explained.
The MRO process for a Vyvanse positive:
- Screening test returns non-negative for amphetamines
- Sample is sent for confirmatory GC-MS/LC-MS/MS analysis — confirms dextroamphetamine positive
- MRO reviews the confirmatory result and contacts the employee directly (by phone)
- The employee discloses their Vyvanse prescription and provides documentation:
- Copy of the prescription label
- Prescriber’s name and contact details
- Confirmation the prescription was dispensed before the test date
- The MRO contacts the prescriber (or pharmacy) to verify the prescription is valid and current
- If verified, the MRO reports the result to the employer as “negative” — the positive is administratively resolved
- The employer typically receives only the final “negative” or “positive” determination — not the clinical details
The nurse Reddit thread captures this process exactly: “If your urine drug screen comes up positive for something they will run it again, this time under a gas spectrometer/mass spectrometry which will tell them the exact metabolites that are present… The MRO will reach out to you and ask about your medications… As long as the MRO can verify the prescription and the fact that you got the medication filled before the drug test then they report the drug test results as negative to the employer”.
The False Positive Methamphetamine Risk: What the Evidence Shows
One of the most clinically important concerns with Vyvanse and drug screens is the possibility of a false positive for methamphetamine on initial immunoassay screening:
Why this happens:Some immunoassay screening panels have cross-reactivity between dextroamphetamine (from Vyvanse) and methamphetamine — meaning the antibodies in the test cannot perfectly distinguish between closely related molecules. Studies document false-positive methamphetamine rates of 3.9–9.9% from amphetamine cross-reactivity on standard immunoassay screens.
The critical resolution:A false positive for methamphetamine on initial immunoassay is resolved by confirmatory GC-MS/LC-MS/MS testing. Confirmatory testing will specifically identify dextroamphetamine — NOT methamphetamine — in a person taking Vyvanse as prescribed. The two compounds are structurally distinct and clearly separable by mass spectrometry.
The practical implication:If an initial oral fluid or urine screen returns a positive for methamphetamine and you are taking prescribed Vyvanse, do not panic — request confirmatory testing immediately. The confirmatory result will exonerate you by specifically identifying the compound as dextroamphetamine, not methamphetamine.
Medications that can cause TRUE false positives for amphetamines:Beyond Vyvanse (which is a true positive — you really are producing dextroamphetamine), other medications can cause false positive amphetamine immunoassay results in people who are NOT taking any amphetamine-class drug:
- Bupropion (Wellbutrin/Zyban) — one of the most common false positive triggers
- Fluoxetine (Prozac)
- Ranitidine (Zantac)
- Trazodone
- Mexiletine
- Pseudoephedrine (common in decongestants like Sudafed)
- Labetalol
The Australian Workplace Drug Testing Context
Australian workplace drug testing operates under a different regulatory framework than the US, with important implications for Vyvanse users:
The AS/NZS 4308 Standard
Most Australian workplace urine drug testing is conducted under AS/NZS 4308:2008(Procedures for specimen collection and the detection and quantitation of drugs of abuse in urine). This standard specifies:
- The drug classes tested (including amphetamine-type substances)
- The initial screening cutoff concentrations
- The requirement for confirmatory testing before a result can be reported as positive
Oral Fluid Testing in Australia
Many Australian industries — particularly mining, construction, and transport — now use oral fluid (saliva) testing rather than urine, conducted under AS 4760:2006:
- Oral fluid tests detect amphetamine-class substances in the 48–72 hour window
- Vyvanse will produce a non-negative oral fluid result if taken within this window
- The Alcolizer workplace safety publication specifically notes: “Prescription stimulants like Dexamphetamine and Vyvanse may cross-react and produce not-negative, unconfirmed results. Disclosure is essential”
Australian Legal Rights for Prescribed Medication
The Australian r/AusLegal community discussion confirms the key legal framework:
- Employers have the right to test under their drug and alcohol policies, which must be disclosed to employees
- Employees have the right to disclose prescribed medication before or after a test — disclosure after a non-negative result is the standard procedure
- A positive for a prescribed medication is not automatic grounds for dismissal under Fair Work Act principles — it is an occupational health matter requiring individual assessment
- Safety-critical roles (mining, heavy transport, aviation) may have more restrictive policies, and fitness-for-duty assessment may be required even for legitimately prescribed stimulants — the concern being whether stimulant medication at therapeutic doses affects safety-critical task performance, not legality
Disclosure Strategy for Australian Workplace Tests
The LinkedIn workplace safety article and Alcolizer publication both recommend proactive disclosure as the primary strategy:
- Inform the testing facility of your Vyvanse prescription before the test if the employer’s policy permits pre-test disclosure
- Keep a copy of your current prescription and a letter from your prescriber readily available
- Be aware that in safety-critical industries, the employer may refer the matter to an occupational physician for fitness-for-duty assessment regardless of prescription status
Key Factors That Affect Detection Time
Several variables influence exactly how long Vyvanse remains detectable:
Factors that extend detection time:
- Higher doses (60–70 mg vs. 20–30 mg) produce higher plasma concentrations and longer detection windows
- Slower metabolism — older age, liver impairment, renal impairment
- More acidic urine pH — amphetamines are weak bases that are reabsorbed rather than excreted in acidic urine
- Chronic daily use may produce marginal tissue accumulation beyond single-dose detection
Factors that shorten detection time:
- Higher urine pH (alkaline urine) — promotes amphetamine excretion
- High fluid intake and urinary frequency — increases clearance rate
- Faster individual metabolism — younger age, no metabolic impairment
- Lower therapeutic dose
Important caveat on hydration:Excessive water consumption immediately before a drug test (“flushing”) may dilute urine below the specific gravity threshold required for a valid sample — producing an “invalid/dilute specimen” result that must be recollected, not a negative. Test administrators check specific gravity and creatinine to detect dilution.
What Vyvanse Does NOT Show Up As
Equally important as knowing what Vyvanse does show up as is understanding what it does notproduce:
- ❌ Does not show as methamphetamine on confirmatory testing — this is the most important reassurance for Vyvanse users
- ❌ Does not show as MDMA or Ecstasy — structurally distinct compound
- ❌ Does not show as cocaine — entirely different drug class
- ❌ Does not show as opiates/opioids — no structural similarity
- ❌ Does not show as cannabis/THC — no pharmacological or structural relationship
- ❌ Does not show as lisdexamfetamine specifically on standard immunoassay panels — only the dextroamphetamine metabolite is detected
- ❌ Does not show as Adderall specifically — both Vyvanse and Adderall show as “amphetamine positive” with no specific brand identification
Common Misconceptions About Vyvanse and Drug Tests
Myth 1: “Vyvanse won’t show up on a drug test because it’s a prodrug.”Incorrect — and a dangerous misunderstanding. Vyvanse’s prodrug nature means the parent compound (lisdexamfetamine) is rapidly converted to dextroamphetamine in the bloodstream. Drug tests that detect dextroamphetamine — which is essentially all standard amphetamine panels — will reliably detect Vyvanse use. The prodrug design makes Vyvanse harder to abuse by non-oral routes; it does not make it undetectable.
Myth 2: “Vyvanse shows up as methamphetamine.”On initial immunoassay screening, some panels may cross-react and produce a methamphetamine signal — but confirmatory GC-MS/LC-MS/MS testing clearly distinguishes dextroamphetamine (from Vyvanse) from methamphetamine. A properly conducted confirmatory test will never report Vyvanse use as methamphetamine use.
Myth 3: “Having a prescription means I can’t fail a drug test.”At the initial screening stage, Vyvanse will produce a non-negative result regardless of prescription status. The prescription resolves this through the MRO verification process — but this is a post-positive administrative resolution, not a pre-emptive pass. In safety-critical industries, a valid prescription may still trigger a fitness-for-duty assessment.
Myth 4: “Stopping Vyvanse a day before a test will clear it from my system.”Urine detection windows are 3–5 days for most patients at therapeutic doses. Missing one dose does not clear Vyvanse from urine — the dextroamphetamine metabolite will still be detected if the medication was taken within the preceding 3–5 days. The only way to ensure a negative result is either to not have taken the medication within the detection window or to have a valid prescription for the MRO to verify.
What does Vyvanse show up as on a drug screen Hobart
What does Vyvanse show up as on a drug screen Devonport
What does Vyvanse show up as on a drug screen Launceston
What does Vyvanse show up as on a drug screen Tasmania
What does Vyvanse show up as on a drug screen Victoria
What does Vyvanse show up as on a drug screen Queensland
What does Vyvanse show up as on a drug screen Canberra
What does Vyvanse show up as on a drug screen Australian Capital Territory
What does Vyvanse show up as on a drug screen South Australia
What does Vyvanse show up as on a drug screen New South Wales
What does Vyvanse show up as on a drug screen Darwin
What does Vyvanse show up as on a drug screen Ghan
What does Vyvanse show up as on a drug screen Northern Territory
What does Vyvanse show up as on a drug screen Australia
What does Vyvanse show up as on a drug screen Austria
What does Vyvanse show up as on a drug screen Germany
What does Vyvanse show up as on a drug screen United Kingdom
What does Vyvanse show up as on a drug screen Sweden
What does Vyvanse show up as on a drug screen Denmark
What does Vyvanse show up as on a drug screen Norway
What does Vyvanse show up as on a drug screen Finland
What does Vyvanse show up as on a drug screen Iceland
What does Vyvanse show up as on a drug screen Netherlands
What does Vyvanse show up as on a drug screen Spain
What does Vyvanse show up as on a drug screen Ireland
What does Vyvanse show up as on a drug screen Switzerland
FAQ: People Also Ask About Vyvanse and Drug Tests
What does Vyvanse show up as on a drug screen?Vyvanse shows up as amphetamine on all standard drug screens. Because Vyvanse is a prodrug that converts entirely to dextroamphetamine in the bloodstream, it triggers the amphetamine-positive response on urine, blood, saliva, and hair immunoassay panels. On confirmatory testing (GC-MS or LC-MS/MS), it specifically identifies as dextroamphetamine — which is clearly distinguishable from methamphetamine. No standard drug screen identifies “Vyvanse” or “lisdexamfetamine” specifically by name — it reports the detected compound class.
Will Vyvanse show up on a standard 5-panel drug test?Yes — the standard SAMHSA-5 panel tests for amphetamines as one of the five drug classes. Vyvanse will produce a positive amphetamine result on this panel if taken within the detection window of 3–5 days (urine). The other four classes tested (marijuana, cocaine, opiates, PCP) are entirely unrelated to Vyvanse and will not be affected.
How long does Vyvanse stay in your system for a drug test?Detection windows vary by testing method: urine 3–5 days, blood 8–34 hours, saliva 48–72 hours, and hair up to 90 days. The most clinically relevant figure for most patients is the urine window of 3–5 days, as this is the most common testing method. Individual factors including dose, age, metabolism, hydration, and urine pH all influence the actual detection time within these ranges.
Can I fail a drug test for work if I take Vyvanse with a prescription?At the initial screening stage, yes — you will produce a non-negative result for amphetamines. However, this does not constitute a final “fail” under standard workplace drug testing protocols. The non-negative result triggers the MRO review process, during which you provide your prescription documentation, the MRO verifies it with your prescriber, and the result is reported to the employer as “negative”. In safety-critical industries, a fitness-for-duty assessment may still be required.
Does Vyvanse test positive for meth?On initial immunoassay screening, there is a documented cross-reactivity rate of 3.9–9.9% that can produce a false positive for methamphetamine. However, on confirmatory GC-MS or LC-MS/MS testing, Vyvanse will be definitively identified as dextroamphetamine — not methamphetamine. Confirmatory testing is required before any positive result is reported as confirmed, and this clearly distinguishes prescribed Vyvanse from illicit methamphetamine use.
What should I do if I have a Vyvanse prescription and need to take a drug test in Australia?The recommended approach for Australian patients is:
- Keep a copy of your current Schedule 8 prescription and a prescriber letter readily accessible
- Be aware that the initial test will likely be non-negative for amphetamines
- Disclose your prescription to the testing facility or MRO as requested — not necessarily before the test, but as part of the review process
- In safety-critical industries (mining, transport), contact your occupational health provider before the test to understand the employer’s policy on prescribed stimulants and whether a fitness-for-duty assessment is required
